Aviceda Therapeutics is winding down after a Phase 2 failure in its geographic atrophy program, according to a source familiar with the decision. The company had planned to move an eye drug into Phase 3 despite the mid-stage setback, but the update suggests the program’s risk profile became untenable. For biotech observers, the shutdown highlights how quickly ophthalmology development timelines can tighten once pivotal efficacy questions emerge in Phase 2—particularly when upcoming Phase 3 funding and trial execution are already resource-intensive. The news also reinforces the broader sector reality that clinical setbacks can rapidly convert platform momentum into asset divestiture or wind-down, depending on the financing runway and partner appetite.